- TABRECTA®(capmatinib)tablets By Novartis is a prescription medicine used to treat adults with a kind of lung cancer called non-small cell lung cancer (NSCLC) that:has spread to other parts of the body or cannot be removed by surgery (metastatic), andwhose tumors have an abnormal mesenchymal-epithelial transition (MET) gene.
The effectiveness of TABRECTA in these patients is based on a study that measured 2 types of response to treatment (response rate and duration of response). There is no clinical information available to show if patients treated with TABRECTA live longer or if their symptoms improve. There are ongoing studies to find out how TABRECTA works over a longer period of time.
It is not known if TABRECTA is safe and effective in children.
How does TABRECTA work?
- TABRECTA works by blocking the activity of proteins made by METex14 that can cause your cancer to grow
- TABRECTA affects both cancer cells and healthy cells
- Although TABRECTA has been studied in people with NSCLC, how TABRECTA works has been demonstrated only in laboratory studies